Monitoring of coronavirus infection in the kyrgyz population

A. Y. Popova, V. S. Smirnov, O. T. Kasymov, S. S. Egorova, Z. S. Nurmatov, I. V. Drozd, A. M. Milichkina, V. Smolensky, Z. Nuridinova, V. A. Ivanov, G. Z. Sattarova, E. S. Ramsay, B. I. Dzhangaziev, E. Zueva, U. U. Arabiy, V. G. Drobyshevskaya, O. B. Zhimbaeva, A. Razumovskaya, A. A. Totolian
{"title":"Monitoring of coronavirus infection in the kyrgyz population","authors":"A. Y. Popova, V. S. Smirnov, O. T. Kasymov, S. S. Egorova, Z. S. Nurmatov, I. V. Drozd, A. M. Milichkina, V. Smolensky, Z. Nuridinova, V. A. Ivanov, G. Z. Sattarova, E. S. Ramsay, B. I. Dzhangaziev, E. Zueva, U. U. Arabiy, V. G. Drobyshevskaya, O. B. Zhimbaeva, A. Razumovskaya, A. A. Totolian","doi":"10.15789/2220-7619-moc-17531","DOIUrl":null,"url":null,"abstract":"Purpose of the study: to study the dynamics of developing herd immunity against SARS-CoV-2 in the population of the Republic of Kyrgyzstan during COVID-19. Materials and methods. The work was carried out using the methodology for assessing population immunity developed by Rospotrebnadzor (Russia) as well as the Ministry of Health (Kypgyzstan) and the St. Petersburg Pasteur Institute. The selection of participants was carried out by questionnaire using a cloud (Internet server) service. To monitor population immunity, a cohort of 2421 subjects was formed, who participated in all stages of seromonitoring. Volunteers were randomized according to age groups (1–17, 18–29, 30–39, 40–49, 50–59, 60–69, 70+ years), regional and professional factors. Antibodies (Abs) against SARS-CoV-2 nucleocapsid (Nc) and the receptor binding domain (RBD) of S-glycoprotein were determined by qualitative and quantitative methods. The study was carried out in 3 stages according to a single scheme: 1st stage — 06/28–07/03/2021, 2nd — 21–25/02/2022 and 3rd — 31/10–04/11/2022. Since 2021, Kyrgyzstan has been vaccinating the population against SARS-CoV-2 mainly using inactivated whole-virion vaccines. Results. Population immunity against SARS-CoV-2 was predominantly accounted for by both Ab types (Nc+RBD+). By the 3rd stage, the percentage of such persons reached 99.2%, Nc–RBD– volunteers — up to 0.8%. At the 1st stage, middle-aged people dominated, but age differences were leveled out by the 2nd stage. The greatest impact on seroprevalence was found among medical workers, the smallest — among businessmen and industrial workers. Populational vaccination significantly impacted on the state of herd immunity that reached 25% by the 3rd stage. The refusals of the population in Kyrgyz Republic from vaccination noted at the 2nd and especially 3rd stages did not significantly affect level of herd immunity, which could probably be associated with asymptomatic cases of COVID-19, against which primary vaccination had a booster effect. Conclusion. The dynamics of population humoral immunity against SARS-CoV-2 included a number of changes in the level of circulating antibodies (Nc, RBD), caused by both primary infection and vaccination. The herd immunity formed in population of Kyrgyzstan allowed to reduce the incidence of COVID-19 to almost sporadic level.","PeriodicalId":21412,"journal":{"name":"Russian Journal of Infection and Immunity","volume":"39 30","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Infection and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15789/2220-7619-moc-17531","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of the study: to study the dynamics of developing herd immunity against SARS-CoV-2 in the population of the Republic of Kyrgyzstan during COVID-19. Materials and methods. The work was carried out using the methodology for assessing population immunity developed by Rospotrebnadzor (Russia) as well as the Ministry of Health (Kypgyzstan) and the St. Petersburg Pasteur Institute. The selection of participants was carried out by questionnaire using a cloud (Internet server) service. To monitor population immunity, a cohort of 2421 subjects was formed, who participated in all stages of seromonitoring. Volunteers were randomized according to age groups (1–17, 18–29, 30–39, 40–49, 50–59, 60–69, 70+ years), regional and professional factors. Antibodies (Abs) against SARS-CoV-2 nucleocapsid (Nc) and the receptor binding domain (RBD) of S-glycoprotein were determined by qualitative and quantitative methods. The study was carried out in 3 stages according to a single scheme: 1st stage — 06/28–07/03/2021, 2nd — 21–25/02/2022 and 3rd — 31/10–04/11/2022. Since 2021, Kyrgyzstan has been vaccinating the population against SARS-CoV-2 mainly using inactivated whole-virion vaccines. Results. Population immunity against SARS-CoV-2 was predominantly accounted for by both Ab types (Nc+RBD+). By the 3rd stage, the percentage of such persons reached 99.2%, Nc–RBD– volunteers — up to 0.8%. At the 1st stage, middle-aged people dominated, but age differences were leveled out by the 2nd stage. The greatest impact on seroprevalence was found among medical workers, the smallest — among businessmen and industrial workers. Populational vaccination significantly impacted on the state of herd immunity that reached 25% by the 3rd stage. The refusals of the population in Kyrgyz Republic from vaccination noted at the 2nd and especially 3rd stages did not significantly affect level of herd immunity, which could probably be associated with asymptomatic cases of COVID-19, against which primary vaccination had a booster effect. Conclusion. The dynamics of population humoral immunity against SARS-CoV-2 included a number of changes in the level of circulating antibodies (Nc, RBD), caused by both primary infection and vaccination. The herd immunity formed in population of Kyrgyzstan allowed to reduce the incidence of COVID-19 to almost sporadic level.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
监测吉尔吉斯斯坦人口冠状病毒感染情况
研究目的:研究吉尔吉斯斯坦共和国居民在 COVID-19 期间对 SARS-CoV-2 产生群体免疫力的动态。材料和方法。这项工作采用了俄罗斯 Rospotrebnadzor 公司、吉尔吉斯斯坦卫生部和圣彼得堡巴斯德研究所制定的人群免疫力评估方法。通过云(互联网服务器)服务进行问卷调查,挑选参与者。为了监测人群免疫力,我们建立了一个由 2421 名受试者组成的队列,他们参与了血清监测的所有阶段。志愿者按照年龄组(1-17 岁、18-29 岁、30-39 岁、40-49 岁、50-59 岁、60-69 岁、70 岁以上)、地区和职业因素进行随机分组。通过定性和定量方法测定了针对 SARS-CoV-2 核头壳(Nc)和 S-糖蛋白受体结合域(RBD)的抗体(Abs)。研究按照单一计划分三个阶段进行:第一阶段--2021 年 3 月 6/28 日-7 日,第二阶段--2022 年 2 月 21-25 日,第三阶段--2022 年 10 月 31 日-11 月 4 日。自 2021 年起,吉尔吉斯斯坦主要使用全病毒灭活疫苗为居民接种 SARS-CoV-2 疫苗。结果。人群对 SARS-CoV-2 的免疫力主要来自两种 Ab 类型(Nc+RBD+)。到第三阶段,这类人的比例达到 99.2%,而 Nc-RBD- 志愿者的比例则高达 0.8%。在第一阶段,中年人占多数,但到了第二阶段,年龄差异趋于平稳。对血清流行率影响最大的是医务工作者,最小的是商人和产业工人。人口接种对群体免疫状态有重大影响,在第三阶段达到 25%。吉尔吉斯共和国居民在第二阶段,尤其是第三阶段拒绝接种疫苗的情况并未对群体免疫水平产生重大影响,这可能与 COVID-19 的无症状病例有关,而初级疫苗接种对无症状病例有增效作用。结论针对 SARS-CoV-2 的群体体液免疫动态包括由初次感染和疫苗接种引起的循环抗体(Nc、RBD)水平的一系列变化。吉尔吉斯斯坦人口形成的群体免疫力使 COVID-19 的发病率几乎降至零星水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Mice microglia cytokine profile changes under the influence of HSV-1 Synthetic thymic hexapeptide in the correction of alterations of antibacterial immune defense and normalization of the profile of proinflammatory cytokines in immunocompromized Children with local unlimited acute peritonitis Balance of pro- and anti-inflammatory cytokines in young patients who passed active Immunization against SARS-CoV-2 during the COVID-19 Pandemic Conserved linear B-cell peptides among the influenza A viral neuraminidases enhance the cross-protective potential of inactivated whole-virion influenza vaccine Characteristics of virus-specific immunological reactions following COVID-19 vaccination in heart transplant recipients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1